Table 2. Clinical description of infected subjects before (BT) and 6Â months after treatment (6M AT)
|  | Baseline—BT (n = 32) | 6M AT (n = 32) | P-value |
|---|---|---|---|
Eosinophils (cells/µl), median (IQR) | 815 (550–1078) | 245 (117.5–367.5) | < 0.0001 |
Eosinophils (%), median (IQR) | 10.45 (6.4–14.55) | 3.16 (1.465–5.6) | < 0.0001 |
WBC (cells/µl), median (IQR) | 7470 (6600–9305) | 7425 (6168–8308) | ns |
S. stercoralis stool exam, n (%) | < 0.0001 | ||
 Positive | 15 (47%) | 0 |  |
 Negative | 16 (50%) | 29 (91%) |  |
 Unknown | 1 (3%) | 3 (9%) |  |
S. stercoralis IFAT titre, n (%)a | < 0.0001 | ||
 ≤ 160 | 11 (34%) | 28 (88%) |  |
 > 160 | 20 (63%) | 3 (9%) |  |
S. stercoralis qPCR, n (%) | < 0.0001 | ||
 Positive | 14 (44%) | 1 (3%) |  |
 Negative | 16 (50%) | 28 (88%) |  |
 Unknown | 2 (6%) | 3 (9%) |  |
Clinical symptoms BT, n (%) | |||
 Present | 22 (69%) | na |  |
 Absent | 10 (31%) | na |  |
Detailed clinical symptomsb, n (%) | |||
 Pruritus | 17 (77%) | na |  |
 Skin rash | 9 (41%) | na |  |
 Abdominal pain/distension | 3 (14%) | na |  |
 Respiratory symptoms | 6 (27%) | na |  |
Clinical symptoms 6M ATb, n (%) | |||
 Improved | na | 13 (59%) |  |
 Persist | na | 7 (32%) |  |
 Ceased | na | 2 (9%) |  |
Response to treatment 12M ATc, n (%) | |||
 Yes | 24 (75%) | na |  |
 No | 8 (25%) | na |  |
Response to treatment 6M ATd, n (%) | |||
 Yes | 22 (69%) | na |  |
 No | 10 (31%) | na |  |